Show simple item record

dc.contributor.authorWhitaker, HC
dc.contributor.authorWarren, AY
dc.contributor.authorEeles, R
dc.contributor.authorKote-Jarai, Z
dc.contributor.authorNeal, DE
dc.date.accessioned2018-06-13T15:02:00Z
dc.date.issued2010-02
dc.identifier.citationThe Prostate, 2010, 70 (3), pp. 333 - 340
dc.identifier.issn0270-4137
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1865
dc.identifier.eissn1097-0045
dc.identifier.doi10.1002/pros.21059
dc.description.abstractBackground Recent genome-wide association studies have shown an association of a SNP two base pairs upstream of the 5' UTR of the microseminoprotein-beta (MSMB) gene with an increased risk of developing the prostate cancer, re-igniting interest in its protein product, MSMB.Methods As one of the most abundant prostatic proteins, MSMB can be reliably detected in tissue and serum.Results It has been consistently shown that MSMB expression is high in normal and benign prostate tissue and lowered or lost in prostate cancer suggesting that it might be a useful tissue biomarker for prostate cancer diagnosis and its levels in serum may be useful as a marker for prognosis. Members of the cysteine-rich secretory protein family and laminin receptors have been shown to bind MSMB at the cell surface and in serum thereby regulating apoptosis. Thus, in the benign prostate, MSMB regulates cell growth, but when MSMB is lost during tumourigenesis, cells are able to grow in a more uncontrolled manner. Both full length MSMB and a short peptide comprised of amino acids 31-45 have been tested for potential therapeutic benefit in mouse models and humans.Conclusions MSMB has potential as a biomarker of prostate cancer development, progression and recurrence and potentially as a target for therapeutic intervention.
dc.formatPrint
dc.format.extent333 - 340
dc.languageeng
dc.language.isoeng
dc.subjectProstate
dc.subjectAnimals
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectDisease Progression
dc.subjectProstatic Secretory Proteins
dc.subjectPrognosis
dc.subjectAmino Acid Sequence
dc.subjectMutation
dc.subjectMolecular Sequence Data
dc.subjectMale
dc.subjectGenetic Variation
dc.subjectBiomarkers, Tumor
dc.titleThe potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/pros.21059
rioxxterms.licenseref.startdate2010-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe Prostate
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.publication-statusPublished
pubs.volume70
pubs.embargo.termsNot known
icr.researchteamOncogeneticsen_US
dc.contributor.icrauthorKote-Jarai, Zsofiaen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record